Breast Cancer Research and Treatment **18**: 199-200, 1991.

Author index, Volume 18

Abrams JS 171
Aisner J 171
Akiyama F 179
Allen DS S93,S131
Amadori D 19

Barnes DM 11
Beck T 149
Beex LVAM 27
Benraad ThJ 27
Berenberg JL S147
Bergman L 189
Bernstein L S11
Bertram B 43
Bonaguri C 19
Boreham J S41
Bradlow HL 155
Bulbrook RD S1,S19, S37,S47,S93,S131
Bulstrode JC S93
Buzdar AU 165

Chaudary MA S19,S73,S103,S115, S127,S131
Chen J S41
Chen L-C S51
Cullen KJ S55

D'Orsi CJ S107
Dairkee SH 57
Dekker G 189
Demers L 83

Eklund G 49
Ethier SP 73

Favoni RE 3
Fossel ET 99
Friedell GH S73
Frisell J 49
Frye DK 165

Gentilini P 19
Gilbert FI S97
Gonzalez JG 11
Goodman MJ S1,S5, S97
Gravelle IH S93
Grove JS S97
Gullick WJ 11
Gutterman JU 165

Hackett AJ 57
Hakes TB 33
Hall FM 99
Hankin JH S135
Hayward JL S1,S19, S47,S73,S93,S103, S111,S127,S131
Hellman S S143
Hellström L 49
Henderson BE S11
Henderson IC S157
Holmes FA 165
Honig SF 119
Hortobagyi GN 165
Huober J 43

Ikenaga M 179
Issell BF S1

Joyce M 141

Kasumi F 179
Kaufmann M 43
Key TJA S41,S47
Kim I 83
Kloppenborg PWC 27
Knapstein PG 149
Koenders PG 27
Koenig KL S23
Kolonel LN S135
Kosano H S27
Koscielny S 125
Koyasaki N 111

Langens R 27
LeMarchand L S119, S135
Lidbrink E 49
Lippman ME 3,S55
Liu J 33
Ljung BM S51
Low G S97
Lundi N 19
Lynch J 83

Macheledt JE 165
Magni E 19
Makita M 179
Manni A 83
McDonagh J 99
Meyer JS 11
Millis RR 11,S73
Mitze M 149
Miura S S19,S103, S127,S131
Miyazaki I 111
Mizukami Y 111
Moore JW S47
Moorthy R 73
Mukhopadhyay B 33
Murai H S103,S127
Murai JT S19,S131

Namba K 179
Nanni O 19
Narayanan R 155
Ngo JL S51
Nguyen B-L 93
Nishi M 179
Noguchi M 111
Nomura AMY S135
Nonomura A 111

O'Malley BW 67
Ohta N 111
Okumoto T S27
Osborne MP 33,155

Paik S S55
Parnes HL 171
Pasqualini JR 93
Pasternack BS S23
Peterse HL 189
Petru E 43
Pike MC S41
Powell DR 3

Riccobon A 19
Rosen N S55
Rosenberg C S23
Rutqvist L-E 49

Saito Y 111
Sakamoto G 179,S181
Saragoni A 19
Sato T S73,S77
Schmäl D 43
Schmidt-Ullrich R 141
Shikata I S73
Shore RE S23
Smals AGH 27
Smith HS S51
Solares G 141
Somell A 49
Sonnenschein E S23
Stemmerman GN S67
Strax P S23
Strax S S23
Suchi T S73,S77
Sugano H 179,S81, S85

Tait N 171
Takatani O S19,S27, S47,S93
Taniola PG S23
Taniya T 111
Tchekmedyian NS 171
Telang NT 33,155
Thomas DB S31
Tiwari RK 33
Tubiana M 125

van Dongen JA 189
van Kerkhoff EHM 189
van Leeuwen FE 189
Vio A 19

Wang DY S41,S47, S63,S93
Wazer DE 141
Weikel W 149
Wolfe JN S89
Wong GY 33

Yee D 3,S55
Yoshida M S19,S103, S127,S131

Zoli W 19

Breast Cancer Research and Treatment **18**: 201-205, 1991.

Subject index, Volume 18

adjuvant therapy
  Japan vs. the West S157-158
age
  and comorbidity influencing treatment choice and survival 189-198
anchorage independent growth
  and transformation in *ras* transfectants 155-163
  antagonistic effect of interferons α and γ on MCF-7 cells 33-41
antiestrogens
  block of estrone sulfatase activity in ER^+ cells 93-98
  see also tamoxifen, ICI 164,384
autocrine growth factors
  and EGF-independence in rat mammary tumor cells 73-81

benign breast disease
  and NMR detection of malignancy 99-110
biological response modifiers
  addition of interferon-α to tamoxifen therapy 165-170
book review
  Advances in Breast Cancer Detection 119-120
breast conservation
  latissimus dorsi transposition to improve cosmetic deformation 111-118

c-erbB-2 oncoprotein
  and histological type in *in situ* breast cancer 11-17
  and TLI in *in situ* breast cancer 11-17
  see also neu oncoprotein
cholera toxin
  and multiple growth factor independence in rat mammary tumor cells 73-81
clinical features of breast cancer
  Anglo-Japanese comparative study S103-S106
comorbidity
  and age influencing treatment choice and survival 189-198
cosmetic breast evaluation
  Moire topography camera, after breast-conserving surgery 111-118

debrisoquine metabolism
  and breast cancer incidence 43-48
detection of breast cancer
  book review 119-120
DFMO (α-difluoromethylornithine)
  inhibitor of ornithine decarboxylase in polyamine synthesis 83-91
diagnosis
  duct endoscopy for evaluation of nipple discharge 179-187
dietary fat
  and survival in Caucasian vs. Japanese breast cancer S135-S141
DNA binding
  and steroid receptor action 67-71
dose-response relationship
  in phase I/II high-dose megestrol acetate therapy trial 171-177
duct endoscopy and endoscopic biopsy
  for evaluation of nipple discharge 179-187
dye retention
  rhodamine 123 in normal vs. malignant breast cells 57-61

EGF
  and multiple growth factor independence in rat mammary tumor cells 73-81
elderly patients
  influence of age and comorbidity on treatment choice and survival 189-198
endocrine therapy
  addition of interferon-α to tamoxifen therapy 165-170
  cell growth inhibition by high E2 does not alter radiosensitivity 141-148
  phase I/II high-dose megestrol acetate 171-177

endocrinology
breast cancer in Japan, Hawaii, and the West S37-S64
endoscopy, duct
and endoscopic biopsy, for evaluation of nipple discharge 179-187
enhancers
in steroid receptor transactivation of gene expression 67-71
epidemiology
breast cancer in Japan, Hawaii, and the West S5-S34
epidermal growth factor
see EGF
estradiol metabolism
and transformation in *ras* transfectants 155-163
estrogen receptor
and IGF binding proteins in cell lines 3-10
and sites of metastasis 27-32
Japan vs. the West S157-158
mechanism of transactivation of gene expression 67-71
vs. TLI and pathological features in breast cancer 19-25
estrone sulfatase
antiestrogen effects on activity 93-98
estrone sulfate
and bioavailability of estradiol in breast cancer cells 93-98
ethnicity
breast cancer in Japan, Hawaii, and the West S1-S158

fluorescence
rhodamine 123 retention in normal vs. malignant breast cells 57-61

galactography
and duct endoscopy for evaluation of nipple discharge 179-187
gene regulation
steroid receptor action 67-71
genetic diseases
and steroid receptor defects 67-71
genetic pharmacology
debrisoquine metabolism and breast cancer incidence 43-48
germinal center hyperplasia
and prognosis in England and Japan S73-S76
growth factors
multiple independence in rat mammary tumors 73-81

heat shock proteins
and steroid receptor action 67-71
HER-2/*neu* oncogene
see c-erbB-2, neu
high dose estrogen therapy
cell growth inhibition does not alter radiosensitivity 141-148
histologic grade
and Ki-67 growth fraction 149-154
and tumor progression 125-140
histology
comparison of British and Japanese breast cancers S77-S79
hormones
endogenous hormones as breast cancer risk factors S23-S26
levels in British vs. Oriental women S41-S50
hypertriglyceridemia
removal of interference in NMR detection of malignancy 99-110

ICI 164,384
block of estrone sulfatase activity in ER^+ cells 93-98
IGF binding proteins
role in IGF-stimulation of mitogenesis 3-10
distribution in breast cancer cell lines 3-10
IGFs
and mitogenesis in breast cancer cells 3-10
in human breast cancer S55-S62
in situ breast carcinoma
c-erbB-2 protein vs. thymidine labelling index 11-17
insulin
and multiple growth factor independence in rat mammary tumor cells 73-81
insulin-like growth factors
see IGFs
interferons
addition of interferon-α to tamoxifen therapy 165-170

antiproliferative effects and gene induction in MCF-7 cells 33-41
toxicity 165-170
intraductal lesions
evaluation by duct endoscopy and endoscopic biopsy 179-187

Ki-67 antibody
prognostic evaluation of growth fraction 149-154

latissimus dorsi transposition
to improve cosmetic outcome in breast-conserving surgery 111-118
loss of heterozygosity
and progression in breast cancer S51-S54

malignancy tests
rhodamine 123 dye retention in normal vs. malignant breast cells 57-61
mammography
breast cancer in Japan, Hawaii, and the West S89-S112
mortality reduction in the Stockholm screening trial 49-56
MCF-7 cells
block of estrone sulfatase activity by antiestrogens 93-98
cell growth inhibition by high E2 does not alter radiosensitivity 141-148
clonal variation in polyamine involvement 83-91
gene induction by interferons α and γ 33-41
polyamines in estrogen-induced proliferation 83-91
polyamines in TGFα secretion and action 83-91
megestrol acetate
phase I/II high-dose trial 171-177
menopausal status
vs. TLI, pathological features, and hormone receptors 19-25
metastasis
in a natural history model of breast cancer 125-140
metastasis patterns
effect of estrogen and progesterone receptors 27-32
metastatic vs. lymphatic spread
in a natural history model of human breast cancer 125-140
MTT dye formation assay
antiproliferative effect of interferons α and γ on MCF-7 cells 33-41

neu oncoprotein
and Ki-67 growth fraction 149-154
nipple discharge
evaluation by duct endoscopy and endoscopic biopsy 179-187
NMR spectroscopy
C-13 vs. H-1 NMR in detection of malignancy 99-110
nodal involvement
vs. TLI, pathological features, and hormone receptors 19-25
nodal status
and proliferative rate in prognosis 125-140
nuclear size
and c-erbB-2 oncoprotein in DCIS 11-17

oncogene activation
and progression in breast cancer S51-S54
oncogenes
see ras, c-erbB-2, neu oncoprotein

pathological features
vs. TLI and hormone receptors in breast cancer 19-25
pathology
breast cancer in Japan, Hawaii, and the West S67-S86
polyamines
and TGFα secretion and action 83-91
progesterone receptor
and sites of metastasis 27-32
mechanism of transactivation of gene expression 67-71
vs. TLI and pathological features in breast cancer 19-25
progestin therapy
phase I/II high-dose megestrol acetate 171-177
prognostic factors
growth fraction evaluated by Ki-67 antibody 149-154

pathological features vs. TLI and hormone receptors 19-25
sinus histiocytosis and germinal center hyperplasia S73-S76
progression in breast cancer
oncogene activation and loss of heterozygosity S51-S54
proliferative rate
and nodal status in prognosis 125-140
growth fraction evaluated by Ki-67 antibody 149-154
vs. histology and hormone receptors in breast cancer 19-25
putrescine
see polyamines

quadrantectomy
latissimus dorsi transposition to improve cosmetic deformation 111-118

radiotherapy
cell growth inhibition by high E2 does not alter radiosensitivity 141-148
ras oncogenes
and immortalization in breast cancer progression S51-S54
transfection and intermediate biomarkers of transformation 155-163
rat mammary tumors
multiple growth factor independence 73-81
recurrence and survival
breast cancer in Japan, Hawaii, and the West S115-S144
response elements
target sequences for steroid receptors 67-71
rhodamine 123
dye retention in normal vs. malignant breast cells 57-61
risk factors
endogenous hormones S23-S26

S-phase
see proliferative rate
screening
breast cancer in Japan, Hawaii, and the West S89-S112
mortality reduction, Stockholm trial 49-56
predictions from a natural history model 125-140
SHBG (sex hormone binding globulin)
and age at menarche in British vs. Japanese women S47-S50
decrease with high triglycerides, and increased free estradiol S27-S29
menstrual cycle variation S27-S29
sinus histiocytosis
and prognosis in England and Japan S73-S76
size of tumor
and probability of metastatic dissemination 125-140
spermine and spermidine
see polyamines
steroid hormone receptors
mechanism of transactivation of gene expression 67-71
Stockholm screening trial
mortality reduction 49-56

T47D cells
cell growth inhibition by high E2 does not alter radiosensitivity 141-148
tamoxifen
addition of interferon-α to therapy 165-170
block of estrone sulfatase activity in ER^+ cells 93-98
TGFα
polyamine involvement in secretion and action 83-91
thymidine labelling index
and c-erbB-2 oncoprotein in *in situ* breast cancer 11-17
vs. histology and hormone receptors in breast cancer 19-25
TLI
see thymidine labelling index
toxicity
high-dose megestrol acetate 171-177
interferon-α 165-170
transformation
intermediate biomarkers in *ras* transfectants 155-163
transforming growth factor alpha
see TGFα

treatment patterns
Japan vs. the West S157-S158
treatment responses
in different racial groups S147-S155
triglycerides
and decreased SHBG, increased free serum estradiol S27-S29

wide resection
latissimus dorsi transposition to improve cosmetic deformation 111-118